Each individual component has its own evidence-base limitations, summarized briefly in the citations below and in greater depth on the respective standalone product descriptions: GHK-Cu substantial human dermal-application literature, much of it cosmetic-industry-affiliated
If no adverse effects occur, increase to 300-500mcg for the remainder of the cycle
Peptides, which are short amino acid chains, demand careful handling and controlled storage conditions
"Health Canada won't approve it as a drug, but it slips through as a compounded natural health product, where the federal safety check basically doesn't happen." Health Canada considers NHP compounding within a practitioner-patient relationship distinct from manufacturing and not subject to the same regulatory oversight
According to CMS billing guidance (Medicare Article A57755), the primary covered indications are pernicious anemia, documented cobalamin deficiency with laboratory evidence, and malabsorption syndromes that prevent adequate oral B12 absorption
Hold it up to a light source
